HK1252172A1 - 用於使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 - Google Patents

用於使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 Download PDF

Info

Publication number
HK1252172A1
HK1252172A1 HK18111573.2A HK18111573A HK1252172A1 HK 1252172 A1 HK1252172 A1 HK 1252172A1 HK 18111573 A HK18111573 A HK 18111573A HK 1252172 A1 HK1252172 A1 HK 1252172A1
Authority
HK
Hong Kong
Prior art keywords
methods
inhibitor
treating cancer
stat3 pathway
kinase inhibitor
Prior art date
Application number
HK18111573.2A
Other languages
English (en)
Chinese (zh)
Inventor
Chiang J. Li
Youzhi Li
Harry Rogoff
Yuan Gao
Janet Huang
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of HK1252172A1 publication Critical patent/HK1252172A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18111573.2A 2015-04-27 2016-04-26 用於使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 HK1252172A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27
US201562153385P 2015-04-27

Publications (1)

Publication Number Publication Date
HK1252172A1 true HK1252172A1 (zh) 2019-05-17

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111573.2A HK1252172A1 (zh) 2015-04-27 2016-04-26 用於使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法

Country Status (16)

Country Link
US (1) US20180250261A1 (enExample)
EP (1) EP3288552A1 (enExample)
JP (2) JP2018514557A (enExample)
KR (1) KR20170141716A (enExample)
CN (1) CN107683137A (enExample)
AU (1) AU2016255034A1 (enExample)
BR (1) BR112017022958A2 (enExample)
CA (1) CA2983468A1 (enExample)
EA (1) EA201792320A1 (enExample)
HK (1) HK1252172A1 (enExample)
IL (1) IL255023A0 (enExample)
MX (1) MX2017013816A (enExample)
PH (1) PH12017501882A1 (enExample)
SG (1) SG11201708506QA (enExample)
TW (1) TW201713329A (enExample)
WO (1) WO2016176190A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2018005444A2 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途
CN116173004A (zh) * 2021-11-26 2023-05-30 上海交通大学附属瑞金医院 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) * 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Also Published As

Publication number Publication date
AU2016255034A1 (en) 2017-11-02
EA201792320A1 (ru) 2018-02-28
JP2018514557A (ja) 2018-06-07
JP2021121629A (ja) 2021-08-26
IL255023A0 (en) 2017-12-31
BR112017022958A2 (pt) 2018-07-17
CN107683137A (zh) 2018-02-09
SG11201708506QA (en) 2017-11-29
WO2016176190A1 (en) 2016-11-03
MX2017013816A (es) 2018-11-12
CA2983468A1 (en) 2016-11-03
EP3288552A1 (en) 2018-03-07
PH12017501882A1 (en) 2018-03-05
KR20170141716A (ko) 2017-12-26
US20180250261A1 (en) 2018-09-06
TW201713329A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
CY1126663T1 (el) Παραγωγα 2,3-διυδρο-1η-πυρρολο[3,4-c]πυριδιν-1- ονης ως αναστολεις της ηρκ1 για τη θεραπεια καρκινου
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
IL289290A (en) Substituted benzyltriazole compounds for cbl-b inhibition, and other uses thereof
CA2983481A1 (en) Janus kinase inhibitor
MY189557A (en) Pyridone compound as c-met inhibitor
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
WO2014052563A3 (en) Novel compounds that are erk inhibitors
WO2016011390A8 (en) Irak4 inhibiting agents
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2016013564A (es) Inhibidores heterociclicos de cinasas.
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
IL287902A (en) Methods of administering certain vmat2 inhibitors
PH12017501523A1 (en) Selective bace1 inhibitors
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
IL286434A (en) Nicoandyl derivatives
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
HK1250944A1 (zh) 用於治疗癌症的方法
WO2018125880A8 (en) Nrf2 activator
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
WO2018005444A3 (en) Methods for treating cancer
WO2015112705A3 (en) Therapeutic combinations for treating cancer